MX380122B - Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas. - Google Patents
Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas.Info
- Publication number
- MX380122B MX380122B MX2018005019A MX2018005019A MX380122B MX 380122 B MX380122 B MX 380122B MX 2018005019 A MX2018005019 A MX 2018005019A MX 2018005019 A MX2018005019 A MX 2018005019A MX 380122 B MX380122 B MX 380122B
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- benzofuran derivative
- derivative
- medicines
- lymphoma
- Prior art date
Links
- 150000001907 coumarones Chemical class 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 abstract 1
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 abstract 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 abstract 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000003444 follicular lymphoma Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 206010042863 synovial sarcoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Furan Compounds (AREA)
Abstract
La presente invención se relaciona con un derivado de benzofurano, su método de preparación y un uso del mismo en medicina. En particular, la presente invención se relaciona con el derivado de benzofurano como se muestra con la fórmula general (I), el método de preparación del mismo, una composición farmacéutica que contiene el derivado, y usos del mismo como un inhibidor EZH2 y en la prevención y/o tratamiento de enfermedades como tumores y cánceres, etc., y en particular usos del mismo en la prevención y/o tratamiento del linforma de no Hodgkin, linfoma difuso de células B grandes, linfoma folicular y sarcoma sinovial, en donde las definiciones de los sustituyentes en la fórmula general (I) son las mismas que aquellas en la descripción. (ver Fórmula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510800975 | 2015-11-19 | ||
| PCT/CN2016/104318 WO2017084494A1 (zh) | 2015-11-19 | 2016-11-02 | 苯并呋喃类衍生物、其制备方法及其在医药上的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018005019A MX2018005019A (es) | 2018-06-13 |
| MX380122B true MX380122B (es) | 2025-03-11 |
Family
ID=58717310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018005019A MX380122B (es) | 2015-11-19 | 2016-11-02 | Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10759787B2 (es) |
| EP (1) | EP3378859B1 (es) |
| JP (1) | JP6828229B2 (es) |
| KR (2) | KR20180081587A (es) |
| CN (1) | CN107428742B (es) |
| AU (1) | AU2016357900B2 (es) |
| BR (1) | BR112018007876B1 (es) |
| DK (1) | DK3378859T3 (es) |
| ES (1) | ES2760510T3 (es) |
| HR (1) | HRP20192209T1 (es) |
| HU (1) | HUE047785T2 (es) |
| LT (1) | LT3378859T (es) |
| MX (1) | MX380122B (es) |
| PL (1) | PL3378859T3 (es) |
| PT (1) | PT3378859T (es) |
| RS (1) | RS59763B1 (es) |
| RU (1) | RU2727198C2 (es) |
| SI (1) | SI3378859T1 (es) |
| TW (1) | TWI718207B (es) |
| WO (1) | WO2017084494A1 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| EP3626239B1 (en) | 2017-05-18 | 2024-07-03 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Ezh2 inhibitor combined with btk inhibitor for treating tumor |
| EP3626715A4 (en) * | 2017-05-18 | 2021-03-24 | Jiangsu Hengrui Medicine Co., Ltd. | CRYSTAL OF A BENZOFURAND DERIVATIVE-FREE BASE AND MANUFACTURING PROCESS |
| JP7295105B6 (ja) * | 2017-11-10 | 2023-07-24 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | ベンゾフラン誘導体の製造方法 |
| DK3746446T3 (da) | 2018-01-31 | 2022-06-27 | Mirati Therapeutics Inc | PRC2-inhibitorer |
| CN110179796B (zh) * | 2018-02-23 | 2023-01-24 | 江苏恒瑞医药股份有限公司 | 一种苯并呋喃类衍生物的组合物及制备方法 |
| CN110563722A (zh) * | 2018-06-06 | 2019-12-13 | 上海青煜医药科技有限公司 | 吡啶或哒嗪并环化合物及其应用 |
| WO2020063863A1 (zh) * | 2018-09-29 | 2020-04-02 | 江苏恒瑞医药股份有限公司 | Ezh2抑制剂与免疫检查点抑制剂联合在制备治疗肿瘤的药物中的用途 |
| EP3950682B1 (en) | 2019-03-25 | 2026-02-11 | Shanghai Synergy Pharmaceutical Sciences Co., Ltd | Preparation method for amide compounds and use thereof in medical field |
| US12421228B2 (en) | 2019-04-22 | 2025-09-23 | Mirati Therapeutics, Inc. | Naphthyridine derivatives as PRC2 inhibitors |
| CN113302185B (zh) * | 2019-04-29 | 2024-04-09 | 上海和誉生物医药科技有限公司 | 苯并呋喃-6-甲酰胺衍生物、其制备方法和药学上的应用 |
| TW202108578A (zh) * | 2019-05-10 | 2021-03-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 6-取代氨基苯并呋喃化合物的製備方法 |
| CN110003187B (zh) * | 2019-05-10 | 2021-11-05 | 南京工业大学 | 一种多氟烷基取代苯并呋喃类化合物及其制备方法 |
| CN110172448B (zh) * | 2019-05-30 | 2020-07-28 | 中南大学湘雅二医院 | 一种滑膜肉瘤细胞系hSS-005R及其子代细胞系 |
| CN112007162B (zh) * | 2019-05-30 | 2023-05-12 | 江苏恒瑞医药股份有限公司 | Ezh2抑制剂与免疫检查点抑制剂、vegfr抑制剂联合在制备治疗肿瘤药物中的用途 |
| CN114269748A (zh) | 2019-06-05 | 2022-04-01 | 米拉蒂医疗股份有限公司 | 作为用于治疗癌症的PRC2抑制剂的咪唑并[1,2-c]嘧啶衍生物 |
| WO2020259667A1 (zh) * | 2019-06-28 | 2020-12-30 | 江苏恒瑞医药股份有限公司 | Tlr激动剂与抗ox40抗体或其抗原结合片段联合在制备治疗肿瘤的药物中的用途 |
| TW202126302A (zh) * | 2019-09-30 | 2021-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ezh2抑制劑與免疫檢查點抑制劑、酪胺酸激酶抑制劑聯合在製備治療腫瘤藥物中的用途 |
| WO2021063331A1 (zh) * | 2019-09-30 | 2021-04-08 | 江苏恒瑞医药股份有限公司 | EZH2抑制剂与含有TGF-β受体的融合蛋白联合在制备治疗肿瘤的药物中的用途 |
| WO2021063332A1 (zh) * | 2019-09-30 | 2021-04-08 | 江苏恒瑞医药股份有限公司 | 一种ezh2抑制剂与cdk4/6抑制剂联合在制备治疗肿瘤药物中的用途 |
| CN112870365A (zh) * | 2019-11-29 | 2021-06-01 | 江苏恒瑞医药股份有限公司 | Ezh2抑制剂和/或parp抑制剂与化疗药物联合在制备治疗肿瘤药物中的用途 |
| CN117956995A (zh) * | 2021-08-30 | 2024-04-30 | 江苏恒瑞医药股份有限公司 | 一种ezh2抑制剂用于制备治疗t细胞淋巴瘤的药物的用途 |
| MX2024004579A (es) * | 2021-10-15 | 2024-04-30 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Metodo de preparacion de derivado de benzofurano. |
| AU2023295387A1 (en) | 2022-06-13 | 2025-01-09 | Treeline Biosciences, Inc. | 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders |
| KR20250023483A (ko) | 2022-06-13 | 2025-02-18 | 트리라인 바이오사이언시스, 인크. | 퀴놀론 bcl6 이작용성 분해제 |
| US20250282742A1 (en) * | 2024-03-08 | 2025-09-11 | Automera PTE. LTD | Benzofuran derivatives for targeting autophagy |
| WO2026021460A1 (zh) * | 2024-07-23 | 2026-01-29 | 江苏恒瑞医药股份有限公司 | 治疗前列腺癌的方法 |
| WO2026128853A1 (en) * | 2024-12-13 | 2026-06-18 | Treeline Biosciences, Inc. | Methods of treating cancer using an ezh2 inhibitor and a tricyclic quinolone heterobifunctional degrader of bcl6 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110275630A1 (en) | 2003-06-02 | 2011-11-10 | Abbott Laboratories | Isoindolinone kinase inhibitors |
| ATE539070T1 (de) * | 2008-02-14 | 2012-01-15 | Hoffmann La Roche | Heterozyklische antivirale verbindungen |
| MX2012012966A (es) * | 2010-05-07 | 2013-01-22 | Glaxosmithkline Llc | Indoles. |
| US8846935B2 (en) | 2010-05-07 | 2014-09-30 | Glaxosmithkline Llc | Indazoles |
| WO2012005805A1 (en) * | 2010-05-07 | 2012-01-12 | Glaxosmithkline Llc | Azaindazoles |
| EP2410171A1 (en) | 2010-07-23 | 2012-01-25 | Ewt Ip B.V. | Wind turbine having a rotor with hub |
| SG180031A1 (en) | 2010-10-15 | 2012-05-30 | Agency Science Tech & Res | Combination treatment of cancer |
| WO2012118812A2 (en) * | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| JO3363B1 (ar) | 2011-04-13 | 2019-03-13 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| TW201733984A (zh) * | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| US9073924B2 (en) * | 2011-09-13 | 2015-07-07 | Glaxosmithkline Llc | Azaindazoles |
| US9730925B2 (en) | 2011-09-30 | 2017-08-15 | Glaxomithkline Llc | Methods of treating cancer |
| WO2013067300A1 (en) | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
| US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| HK1214815A1 (zh) | 2013-04-30 | 2016-08-05 | Glaxosmithkline Intellectual Property (No. 2) Limited | Zeste增强子同源物2的抑制剂 |
| WO2015077194A1 (en) * | 2013-11-22 | 2015-05-28 | Bristol-Myers Squibb Company | Inhibitors of lysine methyl transferase |
| PL3121175T3 (pl) | 2014-03-17 | 2020-06-01 | Daiichi Sankyo Company, Limited | Pochodne 1,3-benzodioksolu jako inhibitory ezh1 i/lub ezh2 |
-
2016
- 2016-11-02 SI SI201630514T patent/SI3378859T1/sl unknown
- 2016-11-02 WO PCT/CN2016/104318 patent/WO2017084494A1/zh not_active Ceased
- 2016-11-02 LT LTEP16865671.8T patent/LT3378859T/lt unknown
- 2016-11-02 KR KR1020187016692A patent/KR20180081587A/ko not_active Ceased
- 2016-11-02 RU RU2018119173A patent/RU2727198C2/ru active
- 2016-11-02 JP JP2018523005A patent/JP6828229B2/ja active Active
- 2016-11-02 RS RS20191628A patent/RS59763B1/sr unknown
- 2016-11-02 BR BR112018007876-0A patent/BR112018007876B1/pt active IP Right Grant
- 2016-11-02 ES ES16865671T patent/ES2760510T3/es active Active
- 2016-11-02 DK DK16865671.8T patent/DK3378859T3/da active
- 2016-11-02 PL PL16865671T patent/PL3378859T3/pl unknown
- 2016-11-02 EP EP16865671.8A patent/EP3378859B1/en active Active
- 2016-11-02 MX MX2018005019A patent/MX380122B/es unknown
- 2016-11-02 KR KR1020257005120A patent/KR20250028514A/ko active Pending
- 2016-11-02 HU HUE16865671A patent/HUE047785T2/hu unknown
- 2016-11-02 AU AU2016357900A patent/AU2016357900B2/en active Active
- 2016-11-02 HR HRP20192209TT patent/HRP20192209T1/hr unknown
- 2016-11-02 PT PT168656718T patent/PT3378859T/pt unknown
- 2016-11-02 CN CN201680013259.7A patent/CN107428742B/zh active Active
- 2016-11-02 US US15/775,958 patent/US10759787B2/en active Active
- 2016-11-16 TW TW105137422A patent/TWI718207B/zh active
-
2020
- 2020-07-22 US US16/935,407 patent/US11059811B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018005019A (es) | Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas. | |
| ZA202206806B (en) | Benzooxazole derivatives as immunomodulators | |
| MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
| PH12017502246A1 (en) | New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| GEP20217211B (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| MX390014B (es) | Compuestos de dinucleótidos cíclicos y métodos de uso. | |
| MX372914B (es) | Derivado de piperidina y metodo de preparacion y uso farmaceutico del mismo. | |
| MY189761A (en) | Quinazoline derivatives used to treat hiv | |
| MX383213B (es) | Inhibidores de tirosina-cinasas | |
| EA201892838A1 (ru) | Новые пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их | |
| GEAP201914680A (en) | New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| EA201890126A1 (ru) | Новые бициклические производные, способ их получения и фармацевтические композиции, содержащие их | |
| PH12015502588A1 (en) | 4`-fluoro-2`-methyl substituted nucleoside derivatives | |
| UA113470C2 (xx) | Піримідинові та піридинові сполуки та їх застосування | |
| MX391221B (es) | Compuestos y composiciones y usos de los mismos. | |
| MX389724B (es) | Compuestos de fenil-2-hidroxi-acetilamino-2-metil-fenilo | |
| EA201591406A1 (ru) | C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич | |
| MX378509B (es) | Compuesto de pirimidina y su uso farmaceutico. | |
| AU2017269673A1 (en) | Pyridine dicarboxamide derivatives as bromodomain inhibitors | |
| TR201819805T4 (tr) | Flavaglin türevleri̇. | |
| MX386761B (es) | Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo. | |
| MX2019001634A (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos. | |
| MX376090B (es) | Derivados de cromeno como inhibidores de las fosfoinositido-3-cinasas. | |
| HK1252245A1 (zh) | 用於治疗癌症的核苷酸 | |
| MX2018004696A (es) | Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos. |